Wire · opportunities
FDA Approves First-in-Class Asundexian for Stroke Prevention
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The FDA has approved asundexian, a first-in-class factor XIa inhibitor, for use with antiplatelet therapy to reduce stroke risk in adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. Clinical trials showed a 26% reduction in recurrent ischemic stroke without a significant increase in major bleeding overall.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You now have a new drug-approved tool to reduce stroke recurrence without raising major bleeding risk overall. This approval opens chances to develop stroke therapies with safer blood clot mechanisms than traditional options.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics